ArticleThe Journal of experimental medicine2008
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness.
Article in The Journal of experimental medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 109 citations in OpenAlex.
- Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.Journal of translational medicine · 2014Trial
- CD8Science advances · 2025Article
- Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire.Journal for immunotherapy of cancer · 2025Article
- Metal-based immunogenic cell death inducers for cancer immunotherapy.Chemical science · 2025Review
- Magnetic Bead-Based Isolation of CD8Methods in molecular biology (Clifton, N.J.) · 2025Article
- EBAG9 controls CD8+ T cell memory formation responding to tumor challenge in mice.JCI insight · 2022Article
- CD8Nature reviews. Immunology · 2022Review
- Activated platelet membrane nanovesicles recruit neutrophils to exert the antitumor efficiency.Frontiers in chemistry · 2022Article
- Renal cancer-derived exosomes induce tumor immune tolerance by MDSCs-mediated antigen-specific immunosuppression.Cell communication and signaling : CCS · 2020Article
- Antitumor immunity targeting fibroblast activation protein-α in a mouse Lewis lung carcinoma model.Oncology letters · 2020Article
- Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention.Seminars in immunology · 2020Review
- A distinct subset of FcγRI-expressing Th1 cells exert antibody-mediated cytotoxic activity.The Journal of clinical investigation · 2019Article
- PD-1 inhibitors dependent CD8OncoTargets and therapy · 2019Article
- Induction of anergic or regulatory tumor-specific CD4Nature communications · 2018Article
- Next-GenerationFrontiers in oncology · 2018Review
- Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.Nature communications · 2017Article
- Targeting neoantigens to augment antitumour immunity.Nature reviews. Cancer · 2017Review
- Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.Scientific reports · 2017Article
- TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.Cancer discovery · 2016Article
- Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches.Cancers · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is sporadic in nature, characterized by an initial clonal oncogenic event and usually a long latency. When and how it subverts the immune system is unknown. We show, in a model of sporadic immunogenic cancer, that tumor-specific tolerance closely coincides with the first tumor antigen recognition by B cells. During the subsequent latency period until tumors progress, the mice acquire general cytotoxic T lymphocyte (CTL) unresponsiveness, which is associated with high transforming growth factor (TGF) beta1 levels and expansion of immature myeloid cells (iMCs). In mice with large nonimmunogenic tumors, iMCs expand but TGF-beta1 serum levels are normal, and unrelated CTL responses are undiminished. We conclude that (a) tolerance to the tumor antigen occurs at the premalignant stage, (b) tumor latency is unlikely caused by CTL control, and (c) a persistent immunogenic tumor antigen causes general CTL unresponsiveness but tumor burden and iMCs per se do not.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.